CTOs on the Move


 
Akouos is a precision genetic medicine company dedicated to developing gene therapies that restore and preserve hearing. Leveraging its adeno-associated viral (AAV) vector-based gene therapy platform, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, the Company was founded in 2016 by world leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy. Akouos has strategic partnerships with Massachusetts Eye and Ear Infirmary and Lonza, Inc
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.akouos.com
  • 645 Summer Street Suite 200
    Boston, MA USA 02210
  • Phone: n/a

Executives

Name Title Contact Details
Stacy Price
Chief Technical Officer Profile
Alan Smith
Chief Technology Officer Profile
Alan Smith
Chief Technology Officer Profile

Funding

Akouos raised $105M on 03/03/2020

Similar Companies

Verseau Therapeutics

Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases.

NanoLogix

NanoLogix is a biotechnology company specializing in live cell, rapid diagnostics. Our kits are simple and reliable rapid test solutions that detect active threat bacteria and other microorganisms 4x - 12x faster than traditional Petri culture technology, and more cost effectively than PCR Protocol.   NanoLogix FlatPack packaging allows for an extended shelf-life that is frequently more than double today's standard. In ongoing shelf-life tests, NanoLogix plates containing TSA media in FlatPacks have maintained nutrient and moisture levels for over two years in cold storage and over one year at room temperature (RT). Other agars have their usable shelf lives extended by varying amounts. NanoLogix plates can be used for isolating microorganisms, total plate count, and for maintaining stock cultures.

Planetrx Com

Planetrx Com is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Glyscend

Founded in 2014, Glyscend is dedicated to the development of a truly revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway.

Princeton Separations Inc

Princeton Separations Inc is a Freehold, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.